OUR BOARD MEMBERSFund+ relies on the experience, vision and leadership of its Board Members
Mark Waer holds a MD degree (1976 ) and a PhD degree in Immunology (1985 ) from the KULeuven. After a postdoc period at Stanford University and a training in internal medicine/nephrology at the Leuven University hospital he became staffmember at the division of nephrology/renal transplantation and in 1992 professor of Nephrology of KULeuven. In 2000 he became medical director of the KUleuven University hospital, in 2005 vicerector for the biomedical sciences and in 2009 rector of the KULeuven. Presently, Mark Waer is honorary rector of KULeuven and chairman of the board of the University Hospitals of KULeuven. Mark Waer has a long standing experience in the field of clinical immunology and development of immunosuppressive drugs in the context of the spin-off company 4AZA from which he was a cofounder or in formal collaboration with major pharmaceutical companies such as Hoechst AG and UCB.
Executive Board Member
Chris Buyse was CFO at ThromboGenics NV from September 2006 until June 2014. He has 30 years of experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign, where he coordinated its acquisition by BASF in early 2007. Before this, he was Finance Director of WorldCom/MCI Belux, and was CFO and interim CEO of Keyware Technologies, In addition, he held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent Board Member of a few companies, mostly active in life sciences such as Celyad and Inventiva Pharma SA.
Honorary Chairman / Board Observer
Désiré Collen holds a M.D. degree (1968) and Ph.D. degree in Chemistry (1974) from KULeuven. His team initially developed t-PA, still the most effective drug for thrombolytic therapy of acute myocardial infarction and ischemic stroke. He has received several scientific awards including the Francqui Prize (1984) and the Health Prize of the Interbrew-Baillet Latour Fund (2006, jointly with P. Carmeliet). He was the Founder and until December 2013 Chairman of the Board of ThromboGenics NV, where his team developed Jetrea for the treatment of vitreo-macular traction.
François Fontaine joined the Board of Directors of Fund+ in December 2016. He has a law degree from ULB (Université Libre de Bruxelles) and a degree in fiscal sciences from the Brussels Management School (ICHEC). He is Fund Manager at SFPI-FPMI (the Federal Holding and Investment Company), one of the main investors of Fund+. He is also Board Member in a few biotech funds and companies such as Epimede, Theodorus, Asit Biotech, PCD Line and Bioxodes.
Independent Board Member
Dr. Debasish Roychowdhury is a leader in the pharmaceutical industry with a strong background in oncology research and development, and regulatory and commercial operations.Debasish was the Senior Vice President of Global Oncology and Head of the Global Oncology Division at Sanofi until November 2013. Prior to that, he served as the Vice President for Development at GlaxoSmithKline and directed the oncology global regulatory and clinical group at Eli Lilly. He served as CMO of Seragon before its acquisition by Roche and also serves as an independent board member of Celyad SA, Radius Pharma, Lytix Biopharma and Imcheck Therapeutics. He is a lecturer in the Department of Biomedical Engineering, MIT. In his academic career, Debasish served as a faculty member at the University of Cincinnati. He was trained at the All India Institute of Medical Sciences, New Delhi and University of California, San Francisco.
Urbain Vandeurzen was in 1980 co-Founder and until January 2013 Chairman and CEO of LMS International, a high-tech company. He was Chairman of the Board of Directors of GIMV from June 2011 until March 2016. From 1996 to 2003 he was already Boardmember at GIMV. Since 2012 he is Director and Chairman of the fundraising campaign “Opening the Future” from KULeuven and of Flanders Make, a flemish strategic research centre. He is Honorary Chairman of VOKA-VEV and he was as Chairman of VOKA-VEV very much involved in defining the transformation programme “Vlaanderen in Actie”. In 2017, he launched and became Chairman of an evergreen private equity investment company with EUR 350 mio capital for investments in ambitious innovative growth companies with a focus on the high tech industries and healthcare sector, excluding life sciences
Independent Board Member
Luc Debruyne was President of Global Vaccines and member of the Corporate Executive Team at GSK (GlaxoSmithKline), a position he was appointed to in 2013, accountable for 17,000 people and growing revenues to more than $7bn in 2018. He joined GSK in 1991 as a commercial strategy director in R&D, and since then has served in multiple capacities in many countries. A business leader with more than 30 years’ experience in the life sciences industry, Debruyne is currently Board Member of the Institutional Advisory Board of VIB Life Science Institute, Strategy Advisor to the CEO of CEPI (Coalition for Epidemic Preparedness Innovations), Life Science Advisory Board Member of Greenlight Biosciences and Research Fellow at KU Leuven (Economics & Business Faculty). Luc Debruyne holds a Master in Physical Education and Kinesiology from KU Leuven, Belgium. He attended a Sustainability Leadership Programme at the Institute for Sustainability Leadership at the University of Cambridge.
Gérard Lamarche is a Director and member of the Standing Committee of Groupe Bruxelles Lambert. In 2019 he joined, as Chairman of the Board, Multifin S.A., the Family Office and anchor investors of ABInBev, and has held Directorships at LafargeHolcim, Total and SGS. In 2000 he joined NALCO (a US subsidiary of the Suez group, world leader in industrial waste water treatment) as Managing Director before being appointed CFO of the Suez group in 2003. Earlier in his career from 1995-1997, Gérard Lamarche joined Compagnie Financière de Suez as Advisor to the Chairman and Secretary to the Executive Committee before being appointed Deputy Director in charge of Planning, Control and Accounting. He graduated in Economics from the UC Louvain and the INSEAD Management Institute (Advanced Management Program) for Suez Group Executives. He also trained at the Wharton International Forum in 1998-1999 (Global Leadership Series).